Delayed Nasdaq 12:00:06 2024-04-16 pm EDT 5-day change 1st Jan Change
3.54 USD +0.57% Intraday chart for NeuroMetrix, Inc. -6.84% -1.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy CI
Ephraim Fields Discloses his Views on NeuroMetrix CI
RS Fund Discloses its Views on NeuroMetrix CI
Transcript : NeuroMetrix, Inc., Q4 2023 Earnings Call, Feb 22, 2024
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value CI
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid) CI
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
NeuroMetrix Announces 1-for-8 Reverse Stock Split; Shares Fall MT
Transcript : NeuroMetrix, Inc., Q3 2023 Earnings Call, Oct 26, 2023
NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Nasdaq Futures -2- DJ
NeuroMetrix, Inc. and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia CI
Transcript : NeuroMetrix, Inc., Q2 2023 Earnings Call, Jul 27, 2023
NeuroMetrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Nasdaq Futures -2- DJ
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia CI
NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting CI
Sector Update: Health Care Stocks Advancing Late Wednesday MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
NeuroMetrix Reports 'Encouraging' Results of Chemotherapy-Induced Peripheral Neuropathy Clinical Trial MT
NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy CI
Chart NeuroMetrix, Inc.
More charts
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
More about the company
  1. Stock Market
  2. Equities
  3. NURO Stock
  4. News NeuroMetrix, Inc.
  5. NeuroMetrix : Earnings Flash (NURO) NEUROMETRIX Reports Q4 Revenue $1.8M